ReviewHepatology international2026
Phosphatidylethanol versus clinical criteria to diagnose alcohol use relapse after liver transplantation: a prospective cohort study.
Review in Hepatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlcohol-associated liver disease (ALD) with concomitant alcohol use disorder (AUD) is a leading indication for liver transplantation (LT). Return to alcohol use after LT (RAULT) affects a considerable proportion of recipients but lacks an objective diagnostic standard. We evaluated blood phosphatidylethanol (PEth) as a direct biomarker of RAULT and compared it with conventional clinical criteria (ClinC).
methodsWe prospectively studied adult patients who underwent LT for ALD between 2008 and 2023. Since 2020, RAULT has been assessed quarterly using both ClinC and PEth (cut-off > 0.05 µg/L). Discordant results were interpreted using PEth as a biochemical comparator, given its higher objectivity and specificity compared with ClinC, although it was not considered a definitive diagnostic standard.
resultsAmong 143 patients (median age 56 years; 29% female; median post-LT follow-up 72 months), during a 3-year comparative study interval, RAULT was identified in 46 patients (32.2%) by PEth and in 69 patients (48.3%) by ClinC. Concordance between the two methods was observed in 98 cases (68.5%): in 63 cases (44.0%) for absence of RAULT and in 35 cases (24.5%) for presence of RAULT. Discordance occurred in 45 cases (31.5%), including 34 ClinC-positive/PEth-negative cases (23.8%) and 11 ClinC-negative/PEth-positive cases (7.7%). Quarterly and semi-annual PEth testing yielded comparable overall RAULT detection rates; however, quarterly testing identified a higher proportion of severe RAULT (16.1% vs. 12.6%). Time since LT independently predicted RAULT according to PEth (OR = 1.17; 95% CI 1.08-1.27; p = 0.0002).
conclusionsClinical criteria may overestimate the occurrence of RAULT after liver transplantation. Quarterly or semi-annual PEth testing provides additional objective insight into post-transplant alcohol use dynamics and may enhance monitoring of patients with AUD following LT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.